v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Income Statement [Abstract]          
Net revenues $ 183,584 $ 158,805 $ 357,639 $ 313,799 $ 655,353
Cost of revenues 41,106 41,472 80,035 79,993 166,879
Gross profit 142,478 117,333 277,604 233,806 488,474
Operating costs and expenses:          
Research, development and clinical studies 51,448 55,833 109,784 109,610 224,544
Sales and marketing 61,684 57,066 120,041 112,858 240,064
General and administrative 39,908 43,955 125,761 88,724 177,666
Total operating costs and expenses 153,040 156,854 355,586 311,192 642,274
Operating income (loss) (10,562) (39,521) (77,982) (77,386) (153,800)
Financial income (expenses), net (1,890) 4,542 (3,728) 12,112 17,550
Income (loss) before income tax (12,452) (34,979) (81,710) (65,274) (136,250)
Income tax 3,206 5,160 5,086 9,184 (23)
Net income (loss) $ (15,658) $ (40,139) $ (86,796) $ (74,458) $ (136,227)
Basic net income (loss) per ordinary share (in usd per share) $ (0.13) $ (0.36) $ (0.75) $ (0.67) $ (1.22)
Diluted net income (loss) per ordinary share (in usd per share) $ (0.13) $ (0.36) $ (0.75) $ (0.67) $ (1.22)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) 116,012,397 111,572,191 115,106,850 110,930,576 111,471,991
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) 116,012,397 111,572,191 115,106,850 110,930,576 111,471,991